Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Biperiden (ausschl. Wirkstärke 4mg), ATC N04AA02 für die Zeit 01.09.26 - 31.08.28 (zzgl. V.-Option 1x12 Mon)

Section 130a Paragraph 8 SGB V allows health insurance funds and pharmaceutical companies to conclude framework rebate contracts for the medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB is carried out by DAK-Gesundheit. For the medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the above-mentioned substance Biperiden (exclusively strength 4mg), ATC N04AA02, DAK-Gesundheit intends to conclude medicine rebate contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine rebate contracts. A rebate contract under the authorisation model for the above-mentioned substance will come into force for the first time on 01.09.2026 and will end on 31.08.2028 (plus extension option 1x12 months). It will end automatically with the entry into force of the exclusive contract, regardless.